This new FDA-approved weight loss drug is taking the world by storm with incredible results.
Ozempic is a game-changer in weight loss, transforming America's health and wallets.
There's a new weight loss drug on the market and it is absolutely destroying the junk food market. Ozempic has taken the world by storm by making weight loss so easy to achieve - and the big brands are feeling it in their wallets. The CEOs of Walmart, Krispy Kreme and others have come out to complain that their revenue is dropping because Ozempic has been making America too healthy over the past few months.
Walmart U.S. CEO John Furner mentioned, "We've noticed a change compared to most people, with less stuff being bought, and people eating less calories." With all of these changes, everyone can get healthier with Ozempic.
In a recent report from Bank of America, analysts led by Bryan Spillane made a statement: by 2030, weight loss drugs will definitely lead to a significant reduction in calorie intake across the United States.
Morningstar's projections also confirm that by 2030, a significant part of the U.S. population will be using GLP-1s, even in a bullish scenario where more people adopt weight-loss medications. It's a surefire change that will significantly impact calorie consumption in the future! Are you ready to reduce your daily calories? You can find out if you’re eligible with a
"GLP-1 medications are smashing the snack and beverage industry for a magnificent transformation!"
"GLP-1 has hit the snack and beverage industry like a wrecking ball," Jorgensen exclaimed with absolute confidence. He didn't hold back in highlighting that sectors like snack and drink brands are in for a complete makeover.
The storm is brewing for brands that rely heavily on snack sales or aren't typically linked to mealtimes, such as Jack in the Box, Taco Bell (owned by Yum! Brands), Dutch Bros, and Starbucks.
According to Stifel analyst Chris O'Cull, "Taking one of these medications, it becomes easier to resist the urge to grab that soda and fries."
"Get ready for a shopping madness! The wave of 'healthier' shoppers grabbing their prescriptions is set to overhaul the entire store completely," Sundaram declared enthusiastically. He expected a massive boost not only for the food section but also for clothing and all those other everyday merchandise departments.
Kroger Health President Colleen Lindholz chimed in, telling Yahoo Finance that these meds won't just change a few things – they're about to trigger an all-out stampede toward healthier food choices. We're talking about a grocery store transformation of colossal magnitude!
Thousands of Americans achieve significant weight loss with personalized prescription plan, no exercise or diet restrictions required
*Results vary based on starting weight and program adherence. Inches lost from hips, waist, chest, thighs and arms in the first month.
These users exercised daily and ate a reduced-calorie diet. Their fat loss is not typical.
Results from RX Path may vary. Medication prescriptions are at the discretion of medical providers and may not be suitable for everyone. G-Plans typically result in 1-2 lbs per week weight loss in 4 weeks, involving a healthy diet and exercise changes. Consult a healthcare professional before using RX Path or starting any weight loss program.
*Based on the average weight loss in three 68-week clinical trials of patients without diabetes who reached and maintained a dose of 2.4 mg/week of GLP-1 treatment, along with a reduced-calorie diet and increased physical activity. See details.
Medication is not included in the cost of the G-Plans Program. But don’t worry, our insurance concierge partners explore all options to help get you covered.
Wegovy® is FDA-approved for weight loss. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed for weight loss.
The trademarks, service marks, trade names (Wegovy® ,Ozempic®), and products displayed on this Internet site are protected and belong to their respetive owners.
Medical treatment is provided by “G-Plans Affiliated P.C.s,” an affiliated network for medical professional corporations and associations.